Table 1.
Descriptive statistics per treatment (data set A)
| AZA | CsA | CYC | FTY | GLAT | IFN | IVIG | Mitox | MMF | MTX | NAT | RTX | Steroids i.th. | Steroids p.o. | TCZ | |
| Patients receiving treatment, n | 46 | 1 | 12 | 2 | 17 | 30 | 3 | 34 | 8 | 5 | 7 | 65 | 5 | 5 | 2 |
| Females, n (%) | 42 (91.3) | 1 (100) | 12 (100) | 2 (100) | 16 (94.1) | 25 (83.3) | 3 (100) | 26 (76.5) | 5 (62.5) | 5 (100) | 5 (71.4) | 54 (83.1) | 4 (80.0) | 4 (80.0) | 2 (100) |
| Age, mean (SD) | 43.8 (12.6) | 43.5 (8.5) | 47 (11.9) | 54.3 (3.4) | 40.5 (9.6) | 37.6 (11.4) | 41.1 (22.6) | 46.8 (13.4) | 53.2 (12.0) | 50.8 (11.9) | 48.4 (10.7) | 46.8 (12.8) | 46.2 (9) | 43.2 (16.4) | 39.2 (8.6) |
| Disease duration, mean (SD), years | 4.4 (6) | 13.4 (8.5) | 4.2 (5.9) | 18.6 (1.4) | 6.1 (5.8) | 5.7 (6.2) | 7.8 (7.9) | 5.4 (5.9) | 5.6 (6.0) | 5.6 (8.3) | 11.6 (9.1) | 4.8 (4.8) | 4.9 (5.1) | 2.7 (3.8) | 6 (2.3) |
| 2006 Wingerchuk criteria fulfilled, n (%) | 33 (71.7) | 1 (100) | 10 (83.3) | 2 (100) | 14 (83.4) | 29 (96.7) | 2 (66.7) | 27 (79.4) | 6 (75.0) | 4 (80.0) | 7 (100) | 50 (76.9) | 4 (80.0) | 4 (80.0) | 2 (100) |
| AQP4-ab-positive, n (%) | 40 (87.0) | 1 (100) | 12 (100) | 1 (50) | 11 (64.7) | 27 (90.0) | 3 (100) | 30 (88.2) | 7 (87.5) | 4 (80.0) | 7 (100) | 57 (87.7) | 4 (80.0) | 4 (80.0) | 2 (100) |
| Treatment episodes n (%) | 52 (19.6) | 2 (0.8) | 14 (5.3) | 2 (0.6) | 17 (6.4) | 32 (12.1) | 3 (0.9) | 34 (12.8) | 8 (3.0) | 5 (1.9) | 7 (2.1) | 77 (29.1) | 5 (1.9) | 5 (1.9) | 2 (0.8) |
| Episodes without attack, % | 67.3 | 50 | 71.4 | 50 | 52.9 | 25.0 | 33.3 | 64.7 | 37.5 | 60.0 | 28.6 | 59.7 | 80.0 | 100 | 50 |
| First-line, n | 31 | 0 | 9 | 0 | 7 | 27 | 2 | 22 | 3 | 1 | 2 | 28 | 1 | 4 | 0 |
| Second-line, n | 10 | 0 | 3 | 0 | 6 | 4 | 0 | 9 | 2 | 3 | 3 | 24 | 3 | 1 | 1 |
| Third-line or more, n | 11 | 2 | 2 | 2 | 4 | 1 | 1 | 3 | 3 | 1 | 2 | 25 | 1 | 0 | 1 |
| Rate of first-line treatments per drug, % | 59.6 | 0 | 64.3 | 0 | 41.2 | 84.4 | 66.7 | 64.7 | 37.5 | 20.0 | 28.6 | 36.4 | 20.0 | 80.0 | 0 |
| Rate of drug as first-line in the cohort, % | 22.6 | 0 | 6.6 | 0 | 5.1 | 19.7 | 1.5 | 16.1 | 2.2 | 0.7 | 1.5 | 20.4 | 0.7 | 2.9 | 0 |
| Treatment duration, mean (SD) days | 475 (477) | 291 (281) | 122 (125) | 77 (21) | 221 (186) | 699 (596) | 488 (331) | 345 (268) | 462 (447) | 363 (335) | 159 (104) | 524 (430) | 418 (309) | 165 (186) | 389 (4) |
| Cumulative treatment, years | 67.6 | 1.6 | 4.7 | 0.4 | 10.3 | 61.2 | 4.0 | 32.1 | 10.1 | 5.0 | 3.0 | 110.5 | 5.7 | 2.3 | 2.1 |
| Annualised attack rate, mean (95% CI) | 0.34 (0.22 0.51) | 0.63 (0.02 to 3.48) | 1.28 (0.47 to 2.78) | 2.37 (0.06 to 13.02) | 1.36 (0.74 to 2.28) | 0.75 (0.55 to 1.00) | 0.75 (0.15 to 2.18) | 0.84 (0.55 to 1.22) | 0.79 (0.34 to 1.55) | 0.40 (0.05–1.45) | 1.97 (0.73 to 4.28) | 0.46 (0.34 to 0.61) | 0.35 (0.04 to 1.26) | 0 (0. to 1.63) | 0.47 (0.01 to 2.61) |
Age and disease duration at treatment start.
AZA, azathioprine; AQP4-ab, antibodies against aquaporin-4; CsA, ciclosporin A; CYC, cyclophosphamide; FTY, fingolimod; GLAT, glatiramer acetate; IFN, interferon-β; IVIg, intravenous immunoglobulins; i.th., intrathecal; Mitox, mitoxantrone; MMF, mycophenolate mofetil; MTX, methotrexate; NAT, natalizumab; p.o., per os; RTX, rituximab; TCZ, tocilizumab.